Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Terveystalo, Webcast, Q3'26

By Inderes10/21/2026, 7:30 AM
Terveystalo

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Ceri Markkula
00:01 - 00:46

Good morning and welcome to Terveystalo Q3 2026 results webcast. My name is Ceri Markkula, and I am responsible for Investor Relations and sustainability at Terveystalo. Today, we will go through our third quarter results and highlights with our CEO, Ville Iho, and our CFO, Juuso Pajunen. After that, we will provide you with a short update of our ARC strategy execution and our strategic objectives. You will also meet our new SVP, Oral Health, Ville Pesonen. After the presentations, there will be time for your questions. But now, let's start with the third quarter highlights. Over to you, Ville.

Ville Iho
00:46 - 08:32

Thank you and good morning. Let's dive straight into the highlights of the quarter we have today. Plenty of things to cover, but briefly the highlights and lowlights of the quarter. Obviously, the lowlight of the quarter was the muted demand environment, which can be seen in our volume development and hence the decline in revenue, which is roughly 3.6%. And that drops through to our Adj. EBIT. Also, even though our service delivery and operations have been working hard to adjust to muted demand, we can see clearly now the operating leverage working in a negative direction for us, with our Adj. EBIT coming down. We remain positive, of course. Also during the quarter, we have seen positive development in our dental services which we will cover thoroughly today. We are progressing with our strategy. We are pushing new products into the market and we are well positioned for the future as we take the next step in our execution and in our journey. Let's double-click on this muted demand environment. We have shown this picture with different segments and underlying factors impacting the demand for quite a couple of quarters. Consumer demand was actually showing positive indications earlier, but September, in particular, saw a dip in our demand. It can also be seen in the consumer confidence, which went down during September after some months of a positive trend. Our biggest business suffered from a decline in occupational healthcare demand and visits, both in preventive and health services. Health services. Healthcare visits and demand in the market are clearly down. We have made some adjustments to public statistics. There are some discrepancies in the data which are showing healthcare appointments in occupational healthcare dipping 10%. Our management adjustment suggests that it is actually 5%. But anyway, it is still negative and can be seen in the environment and in our numbers. Then finally, the number of employed people in Finland is stable. No clear uptake just yet. And the attrition within the current agreements and current customers in occupational health. Healthcare has been visible throughout. Now, for a couple of quarters. And that has still continued to a certain extent; of course, with the more positive trends now in the economy, we are expecting this to start correcting itself and impacting also our numbers positively going forward. A negative demand environment is visible across all of our segments. Healthcare services took a clear dip down, also in portfolio businesses, but within portfolio businesses. Of course, we have a good news story with dental, which we will discuss today and present our future view on that very important new growth factor for Terveystalo. Sweden still has a very muted demand environment. Even though we are winning in market share there. All in all, a disappointing quarter from Terveystalo's point of view, but the underlying demand going forward into the coming years, next year and 2028, and underlying trends like demography will provide an ample amount of demand for our services. We just need to adjust to the new expectations from our customers, be it public, corporate, private, or insurance customers. Actually, there are a lot of positives within our development inside Terveystalo. And there is one clearly negative factor that has been taking the numbers down during the last couple of quarters. And that is obviously our biggest demand driver, occupational health care. In that area. We have worked hard in renewing our services and our sales and account management activities, and we are making clear progress, especially when it comes to large accounts. So there we are growing again with large customers. There is still a lot of work that we need to do with SMEs to repackage our services to make them easier to buy, use, and pay for. But we are making a turnaround here. We expect the number of connected employees to start growing again during the first quarter of 2027. Healthcare requires transformation from the customer's point of view. Healthcare service companies are no longer just waiting for patients. For patients to pop in. For. A doctor visit is sort of past history. We need to reach out to the customer to look at the actual customer needs and the different ways we can help our patients and customers along the way. We have been planning, within our strategy, new packages and new types of services. We have now launched the first pilot in continuous care modality, a highly digitally driven, continuous care service offering under the Wellby brand. And that is the first service that we are providing through that platform, which is obesity management. It is a pilot phase, but we believe that this type of new service will be answering the developing and increasing customer demands, and we will increase services. These types of services. We will launch the final platform for obesity management during Q4. In the piloting phase, we are testing. We are. We are conducting trials. For acquiring customers. What type of service design changes do we need to implement? But this is part of the future. This is part of the strategy execution, which we will deep dive into later during the presentation. With this, I will, for the final round, actually give the floor to CFO Juuso Pajunen.

Juuso Pajunen
08:33 - 18:02

Thank you Ville. So, thank you all. As Ville said, this will be my final quarterly results presentation with Terveystalo, number 16 in total after four years with the company. So, thank you to all stakeholders, investors, and analysts for following my presentations for these releases and, obviously, other matters. But let's go to the Q3 results. So, all in all, if we look at this page, one can only be disappointed in each and every KPI. You see the negative sign in front of those. And it is absolutely not something that we can be happy with. The market was challenging. And during the quarter, we saw a decline throughout the market and within our services in both public and private sectors. Occupational health was especially challenged by fewer connected employees and a lower visit per employee ratio. But at the same time, if we look a bit underneath the hood, we were able to reduce the variable costs at the pace of the decline of revenues and protect our profitability. It has been a good achievement, but in a seasonally low quarter. In any case, the fixed expenses also pushed through and the profitability is reduced. Then, on a positive note, we closed the transaction and we have successfully started the integration. And you will hear a bit more on that later today. So looking at the whole group, the lower revenues were impacting the profitability. Despite the efficiency actions we have taken, every segment declined. Healthcare services were pressured by the occupational health portfolio businesses due to outsourcing contracts, but the positive movement in dental supported the revenues. Sweden had a slow start after the summer, which is visible on both the revenue and Adj. EBIT. As I said, we were successful in protecting the profitability with defensive measures in variable costs. And finally, the adjustment items mainly relate to topics concerning the acquisition. With the biggest item being the transfer taxes within that at 4.1 million. Then come the advisory fees related to the process. And everything else is minor in that number. Looking at healthcare services, lower revenue and changes in sales mix impacted profitability. All in all, the market was weak. Morbidity was 15% below previous years. You will see a bit more detail on the following slide regarding that. The start of the summer in occupational health was also quite slow. At the same time, when the visits were on a low level, it is good to know that our sales mix was weaker than usual, which is seen especially in the diagnostics and particularly within diagnostics in the laboratories. That pushed the service mix, sales mix, and pricing to negative territory during the quarter. Also, if we go on to the volume development, that continued to be challenging. The main contributors to the changes in visits remain pretty much the same as in previous quarters. Morbidity was low during the quarter, 15% down compared to the previous year. At the moment, we are reviewing our medical leadership forecast for the full year. It points out that in Q4, morbidity starts to increase and the total levels during Q4 are above previous year Q4 levels. We are assuming the peak to occur in late November or early December. But as you all understand, these forecasts are based on the best information available today and are subject to volatility in occupational health. The story continued, but the decline is stabilizing and, like Ville has explained, we are progressing, especially with the large accounts, and now turning our eyes more and more to small accounts and out-of-pocket revenue. That was during the summer and immediately after the summer. The negative trend was broken in September, even though it was supported by Kela 65, those visits are now also in the comparable numbers from previous years. So all in all, combined consumer and insurance demand was actually stable during the quarter. But the trend that we saw during summer did not continue during September. And at the moment, we are evaluating how we proceed into Q4. Portfolio businesses outsourcing contracts revenue declined as expected. As you know, these are nowadays margin contributing. So when we are reducing these revenues, it has an impact on Adj. EBIT. Also, on a positive note regarding the public sector, we have now seen that, especially in staffing services, the volume is growing. However, the price level is inherently lower than a couple of years ago. Dental is the bright spot. We have seen both organic growth within the Terveystalo services. And then we have added Hohde to revenues, which has contributed some €5.5 million to total revenues. And as you see, 6.2 million, up 5.5 from Hohde, you see that we have a healthy organic growth also underneath in the Terveystalo operations. The other includes the divestment of child welfare that was announced earlier this year. In Sweden. Revenues have been pressured by the slow macro environment and market conditions. The start of the summer was the slowest in the consulting world. That of course impacts our revenues quite quickly. If we take comparable currencies, EBITDA was actually improving year on year. But in euro terms, it was slightly down both in absolute and relative terms. Moving forward to the balance sheet. Our cash flow continues to track the income statement steadily. So the decline that we see on a year-on-year basis or LTM basis is pretty much what we have lost on the profitability side. And then from the Q1 tax payments from strong 2025 profits, net debt to adjusted EBITDA is at 2.9, reflecting now the acquisition. And now we are pretty much within our financial target of 3.0. Moving on to the market. The demand environment was challenging in Q3, weaker than we originally expected. During the summer. The change there is mainly in the consumer market that, as explained, did not behave post-summer as we were expecting. As all the trends pointed out, if we look at the next 12-month outlook, it has not materially changed. We do see that there is positive development expected in the consumer and insurance market, especially in dental, where we are continuing our solid performance. As I said, this was the bright spot for the quarter in any case. And then Sweden, where we are net positive and capturing market share. We expect to little by little improve also from the market perspective. So all in all, we are expecting gradual improvement during the next 12 months. Then, moving to guidance, you have likely heard our updates from yesterday or seen them. So we have updated our guidance for 2026. We expect the full year 2026 to show steady performance. Adjusted operating profit is expected to be between €110 and €120 million. January. September was clearly below the levels of the previous year, and the demand development has been weak. Now, within this guidance, we have taken the weak post-summer demand environment into account, and we are not expecting material improvements in the market conditions for Q4, and we expect the challenging environment to continue. The revenue from outsourcing operations in the portfolio businesses is expected to be -€25 million for the full year, and the guidance includes Hohde, but does not include anything from Silmäasema or any other significant acquisitions. Regarding Silmäasema, we are progressing with a close dialogue with the competition authorities, and we have communicated during the summer that closing is expected to take place either this year or in Q1 next year as time goes by. This year, closing is becoming less and less probable, if I put it that way. Then with these words, I would like to invite our CEO, Ville Iho, on stage to update you on the strategy.

Ceri Markkula
18:03 - 18:43

Thank you, Juuso. So as you said, we will zoom out for a while and take a look at our strategy. And as we have communicated, we decided to postpone our Capital Markets Day from December this year to next spring. By then, we expect to have completed the Silmäasema transaction, and to be able to provide you with a clearer view of strategy, execution, and the long-term value creation potential of that combined business. Ville, as you take us now through our strategic objectives and progress so far. Could you start by reminding us why this was the right time to update our strategy?

Ville Iho
18:43 - 28:30

Absolutely. Thank you. As I said earlier in the presentation, healthcare services need to transform and reach out to actual customer needs. This has been a very conservative industry with very conservative ways of serving customer and patient needs. The underlying demand is clearly a positive and strong point. Underlying demand continues to grow. There is no question about that. People will age. People will want more services for their health, healthcare, and well-being needs. But how they consume it, how they buy it, and how they compare different services is going to be different, and it needs to be modernized also by the service providers. We have seen this development now for, let's say, two years. And we have prepared for our strategic pivot. And we have, of course, already clear actions ongoing with our new strategy. ARC. Basically, it comes from our stance on three equally strong pillars. The most important one is the customer. As I said, this industry needs to transform to be more customer-centric and build services and ways of serving based on actual customer needs to reach out to the customer. That only will enable us to capture the growth. Underlying growth is evident in the market, and only through technology can we capture it. Technology can. Can we do it in a profitable way? So this is the triangle that we will work on with our strategy and with our execution. This is the time to pivot. We have six specific strategic objectives under our strategy umbrella. Number one, as I said, is the core of everything. Basically, build a truly customer-centric healthcare services company. Sounds trivial, but looking at the tradition for 2,000 years for this type of service, that is not the case. We have been patient-centric, but that is not enough for future years and decades. Our number three priority in the middle is to grow and diversify. We need to create a more diversified ecosystem around customer healthcare and wellbeing needs and diversify. Diversify our portfolio. Of course, we have actions in place for that one. As you have seen with the Hohde Group acquisition and Silmäasema deal, we need to transform healthcare delivery to reach out to the customer in a profitable way. We need to invest in technology to make the actual services efficient, smooth, easy to use, and easy to buy. Number four: make healthcare easy and engaging. Engaging is really about transforming the current service modalities, which have been. As I said earlier, we are moving away from passively waiting for the patient to appear. The appointment room to clear service packages. Clear. Clear, sellable, and viable service packages. Easy to buy. Easy to use. Easy to compare. Easy to track. Easy. Easy to. Also check after. After the fact. What really caused it? Number five, we need to scale continuous digital services and reach out to the customer. We have launched the piloting phase of the Wellby platform during Q3, and we continue now to build on that. There are episodic needs which are reactive also in the future, which is the healthcare tradition to take care of those. But there are more and more continuous needs. Whether it be chronic conditions, obesity, or a certain time in your life where you need a specific type of support. Finally, number six, which is very much in the core of our classic operation, is reinvented corporate health. There are many ways we can support companies and corporates in their journey with workability and wellbeing management. We just need to, especially for the smaller customers, repackage it, make it clear, and make it easier to buy, easier to understand, easier to use, and easier to check. These are the six clear and concrete targets that we continue working on with our ARC strategy. We are presenting clear and concrete examples of where we are already making progress. We are when. When we are talking about digital platform scaling, we are making healthcare more efficient and smoother. We have launched our platform. We continue scaling that one. We have our 10x initiative where we are basically making our digital appointments 10x more efficient. We have embedded AI into different journey points, to the customer journey and also to the professional journey in their workday. And we continue to do that. There is loads of potential in healthcare services delivery inside the company and with our customers, with their processes, to make this more efficient. Strategic M&A is again diversifying and growing the portfolio. That is very clear. We have made the Hohde Group deal, which is now in the integration phase, gathering steam and going really well, which we will hear more about in just a minute. We have made the Silmäasema acquisition and continue preparing for its integration. All in all, our portfolio next year will look more diversified and give more potential to work on more. With more than 2 million customers that we serve in more and more frequent ways. Making healthcare easy and engaging. We have packaged our core services. We have launched the Wellby platform. We are pricing in a more transparent way. We are making things easier for the customers to track, follow, and manage their care and service journey. And finally, within occupational health care, we have basically renewed almost everything during the last year and a half. The most visible rollout across the board that customers are seeing today is Terveystalo Leo, a modern occupational health care platform, which provides more transparency for the customers and more precise risk assessment. And hence, more precise and accurate interventions create value for our customers, and the rollout will continue during H1. All in all, we are making clear progress already and see ample potential going forward in executing our strategy. Our strategy, of course, is related to our financial targets, which we renewed and disclosed in conjunction with our strategy. Disclosure. Again, 10% EPS growth, and a net debt to adjusted EBITDA ratio of less than 3.0x. Net debt to adjusted EBITDA level and 50% annual distribution of net results. With that, it was not the final time. So you will come once more to the stage, please.

Juuso Pajunen
28:30 - 30:40

Thank you. There always needs to be a comeback. So very briefly, a reminder for all that in 2027, we will update our reporting structure to provide further clarity and transparency on how our different segments are doing. We will report healthcare services, oral health, public partnerships, and Sweden as segments starting from January 2027, and comparable figures will be provided before we publish the Q1 2027 report. And obviously, it is clear, as stated also upon the acquisition of Silmäasema, that as we get the approvals, Silmäasema will become a segment in our reporting structure. Then, let us remind all of ourselves on what we acquired with that group. It was announced on December 23rd of last year. The enterprise value is €88 million, which corresponds to roughly eight times EBITDA including fully burdened synergies. Now on past EBITDA. Remember to also use Finnish accounting standards. Synergies are roughly €4 million within the next couple of years. The expectations are €56 million once again in Finnish accounting standard revenues and roughly €6.4 million in Finnish accounting standard EBITDA. Combined revenues for 2025 are roughly €108 million. Then, within Terveystalo, we have successfully started the integration, with synergy capture already commenced and progressing. What we have learned until now is that Hohde is stronger than Terveystalo, especially when it comes to supply management, and at the same time, Terveystalo is stronger in some processes, such as recall. So, we truly see a best-of-both-worlds scenario meeting with this acquisition. But without further ado, let's invite Mr. Ville Pesonen on stage to explain and give you a deep dive into what oral health actually is at Terveystalo.

Ville Iho
30:44 - 34:05

Thank you. It is really nice to be here for the first time. So it's my first time here. My name is Ville Pesonen. I am the SVP of Oral Health here at Terveystalo. My background is that I am an oral and maxillofacial surgeon by profession. I started as a director of outsourcing services for dental business at Attendo. After that, I practiced in several private dental clinics as an oral surgeon. And then I founded a group 12 years ago and worked as a CEO in the group. Regarding the dental care market. The total market in Finland is approximately €1.3 billion. When we add these numbers. Also, the private dental care market, excluding the public sector, is approximately €700 million per year. It has been growing steadily by 2% per year in former years and will continue to grow. Our estimate is that it will grow approximately 5% per year going forward. The dental care market is a stable and well-functioning system, and the private sector plays an important role in the dental care system in Finland. And we know that the public sector has long waiting times and has been limiting its investments in dental care. And we see a really good opportunity here for the private players. Talking about Terveystalo's oral health business, our goal is to become a leader in oral health, and the acquisition of Hohde Group supports that development, as oral health is one of Terveystalo's selected growth areas. Now with the combined numbers, we have 1,500 dental professionals working with us with high NPS numbers, totaling 77 sites, from which 63 are dental clinics and 14 are dental laboratories. Regarding our dental clinics. We offer broad services, almost everything that you can get from a dental clinic. We offer a comprehensive range of services. So there will be. We provide general dentistry, specialist dentistry, and dental hygiene services. From the laboratory side, our highly skilled experts are working in close cooperation with our dentists and our customers. And we also offer almost everything that a dental laboratory can produce. So prosthesis, mouth guards, and crowns and bridges, and also specialist dental technicians work directly with the customers. That concludes my presentation, and now we will move forward.

Ceri Markkula
34:07 - 34:14

Thank you. Now it's time for a Q&A. And let's start with questions from the phone lines.

Operator
34:16 - 34:39

If you wish to ask a question, please dial star five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial star five again on your telephone keypad. The next question comes from Sammy. Sammy from Danske Bank Markets. Please go ahead.

Unknown 1
34:42 - 35:18

Hi. I have several questions. We will take these one by one. Firstly, starting from connected employees, you lost connected employees on a sequential basis in the third quarter, even though I think you were previously assuming that you would be able to grow the base during the second half of the year. And then you are expecting growth in Q1. So the first question would be, when you talk about Q1, are you assuming that you would have growth on a year-on-year basis starting in Q1?

Juuso Pajunen
35:21 - 35:48

Yes. So basically, yes, actually we updated after the H1 that we have limited expectations on growth. What about occupational health for the second half? Regarding the gradual growth in Q1? We mean that from Q3 2026 to Q4 2026 numbers, we are expecting Q1 2027 to reach higher levels compared to the order stock we have today. That is what we mean by the statement.

Unknown 1
35:50 - 36:05

Okay. And then I mean, on visibility for this Q1 growth. So you said that you've been making progress with large customers. So have you been winning this year already? So it is in a way certain that that growth will happen.

Ville Pesonen
36:06 - 36:36

Well, let me take that one. So it is a combination, as we have discussed earlier, of deals that are already basically done. And then our win rates count the cases that we are now dealing with. So we have both; we have a sort of view forward with the forecasting based on the current win rates. And then we have already closed deals.

Unknown 1
36:39 - 36:48

Okay. And then, what were the main reasons why you didn't achieve this sequential growth during the second half of the year?

Ville Pesonen
36:50 - 37:43

Twofold. Basically, we discussed earlier that, especially the large account counts were sticky. And even though the sales funnel has been rich during this year, really the timing of getting the deals done and also the stickiness of the deals early this year was higher than we expected. It is also basically the case that growth in large accounts has been pushed forward. But we see clearly that that is now starting to happen. Then we still had churn in SMEs and also losses in the employment levels within our existing customers. So that is really the combination.

Juuso Pajunen
37:43 - 38:02

But I would like to remind you that from Q2 2026 to Q3 2026, the biggest impact is actually the summer employees. So there is a seasonal component where it is practically impossible to grow the absolute number from Q2 to Q3. So that one needs to be always remembered when we are discussing this figure.

Unknown 1
38:04 - 38:10

Okay. And then, what about Q4? Are you expecting sequential growth in Q4?

Juuso Pajunen
38:12 - 38:20

Well, as I stated in the guidance, we do not anticipate improvements in Q4. Not on the market, nor on occupational health.

Unknown 1
38:24 - 38:42

Okay. And then you are quite negative regarding Q4 as per the new guidance assumptions. Is this mostly related to occupational health? You have not made the progress you previously anticipated.

Juuso Pajunen
38:43 - 39:12

If I comment and I can then contribute further, our Q4 guidance is based on our assessment that the Q3 market environment was extremely challenging and we have assumed that market environment will continue for Q4. So we are not expecting material improvements in occupational health. We have also now been modest with our expectations when it comes to consumer behavior. And these combined lead to the current Q4 guidance.

Ville Pesonen
39:13 - 39:56

Yes, exactly. Our forecasting routine is such that it now specifically takes into account the lower figures from September. Our early expectation was that the ramp-up from the summer season to the first actual active season for the healthcare services would be steeper and higher. But now, we are basically basing our Q4 forecasts and assumptions on the lower volumes that we saw during September. We updated our forecasting.

Unknown 1
39:57 - 40:11

And what is your assessment regarding the fact that consumer confidence has been improving in both Finland and Sweden? Why isn't that translating to stronger growth? If we think about your business.

Ville Pesonen
40:11 - 41:18

I can start and Juuso can continue. Basically, we see positive development in the most dynamic consumer segment, which is dental. So, we see growth clearly there. But for the rest, it was actually a little surprising for us that, coming from summer to September, consumer demand did not continue to follow the earlier positive development and signs of improvement in consumer confidence. But that more negative view has now been taken into account in the Q4 figures. It can be. So that September is a dip. It is an anomaly. And the consumer demand will start growing more rapidly again. But as of today, we are prudent, and we have taken a more realistic view on the rest of the year.

Unknown 1
41:20 - 41:43

Okay. And then on the full year cash flow outlook, you are not guiding for it, but if we look at the first three quarters, it is roughly half the level of last year. And also net debt to EBITDA is close to your financial target. Where do you see yourself? At the end of this year before the Silmäasema acquisition?

Juuso Pajunen
41:45 - 42:24

Well, first of all, the cash flow has been tracking very carefully the operating performance, the only deviation is the taxes paid out in Q1 from the strong 2025 profits. And that is something we expect to continue. So our cash flow will track our operating performance in Q4. You obviously know that we have paid out dividends in October. So that will be a negative component. And then, traditionally, Q4 has been strong. When it comes to cash inflow. And that is where we are basing our expectations at the moment.

Unknown 1
42:27 - 42:38

Okay. And then my final question would be on the one-off costs in the third quarter, €4 million. Can you elaborate on this in a bit more detail? Do you expect more in Q4?

Juuso Pajunen
42:39 - 43:07

Yes, the €4 million in Q3 are materially coming from the Hohde Group transaction. So the biggest component in there is the transfer taxes that were €1.7 million in total, or roughly €1 million. Then we have different types of success fees. As you know, this was a structured process where we used advisors. We had a very thorough and comprehensive FCCA process. The legal fees were significant. A material part of that €4 million is related to that transaction.

Unknown 1
43:09 - 43:11

Okay. Thanks. I don't have any further questions.

Operator
43:16 - 43:22

The next question comes from Joni Sandval from Nordea. Please go ahead.

Joni Sandval
43:23 - 44:11

Yes, thanks. Thanks for the presentation. I have one question left. Following the week, actually, regarding morbidity, what we have seen in 2025 and also in 2026. It seems that in early Q4, the situation has even weakened further. Are there actually any structural changes in the market or the behavior of customers? So I am just trying to figure out if this is some kind of new baseline, or as you mentioned, you are expecting higher morbidity year over year in Q4, but it seems that this has been a weak performance on the morbidity side. So any comments around this would be good.

Juuso Pajunen
44:11 - 45:18

If I start, and we can then complement first of all the morbidity, our visibility starts to improve in late August, and then you start to have better visibility on forecasts around mid-September. And from that point onwards, our forecast has been fairly accurate. It was very low during August, then slightly improved during September, so that the full quarter was roughly 15% down. Now the start of October, week 41 was on a weaker note. Week 42 is relatively less down, and it seems that this is behaving as we forecast in our projections. We take into account our own data plus then the Finnish. What is THL in English, our administrative data. And based on that, we do so. At the moment, we do not see a disconnection between our forecast methodology and the outcomes, which indicates that the change in behavior is not material. But obviously, we cannot rule that out either.

Ville Pesonen
45:20 - 45:54

Yeah, maybe the only thing to add is that when looking at occupational health care use frequency, we ourselves have been pushing for, for example, self-notification processes for our customers. To a certain extent, that can be seen as resetting the conversion from these respiratory conditions to our services. But it is more like resetting the base. It is not a continuous trend.

Joni Sandval
45:56 - 46:15

Okay. Okay. And my second question is still on portfolio outsourcing deals. Is there any more, or should we expect the run rate to be here now, or is there still downside on the profitability of this? So. So do you have some contracts that are still ending in the Q4?

Juuso Pajunen
46:15 - 46:43

Basically our guidance was a 25 million reduction this year, which means that there is a 5 million reduction still in Q4 compared to the 19.7 or pretty much 20 million reduction year-to-date. At the end of Q3, we have one contract remaining, which is expected to generate revenue also in 2027. But obviously these are something that may also end depending on how different items are being negotiated.

Joni Sandval
46:45 - 46:47

Okay. Thank you. That is all from me.

Operator
46:51 - 46:56

There are no more questions at this time. So I hand the conference back to the speakers.

Ceri Markkula
46:57 - 47:11

We have some questions from the chat. Some have already been answered. But there is a question about the share of large customers in occupational health versus SMEs in our segment.

Juuso Pajunen
47:12 - 47:27

We have not commented on this in detail, but one can estimate that roughly two-thirds of our customers are large accounts, while roughly one-third are SMEs. Now with this type of view.

Ceri Markkula
47:29 - 47:40

And a question about Solo Health. Can you go through your rationale? Why was that attractive as the staffing market still seems to be declining and prices are going down?

Juuso Pajunen
47:40 - 48:20

Yeah. If I look at Solo Health, this is always something that we want to be in the public sector. We have been progressing there, and sometimes opportunity meets in the middle. So we would be gaining good services in pockets where we are not that strong in terms of staffing, and how you slice and dice that market between emergency care, elderly care, and so on. So it will be a solid combination with a highly synergistic deal on that one. And then when the price is right, we are obviously happy to take such moves that would contribute to our shareholder value.

Ville Pesonen
48:21 - 48:35

Yeah. The only thing to add is that, of course, we have taken our own view on the market development, past and future, and even reflecting that one. The deal is sound.

Ceri Markkula
48:38 - 48:50

Then a question about covenants. Your covenants are based on net debt to EBITDA, among other metrics. But can you comment on what the threshold is and if it is based on adjusted or reported EBITDA?

Juuso Pajunen
48:51 - 49:21

I do not think we have commented publicly or published a covenant level, but it is fair to say that we are talking about adjusted EBITDA figures, and we have very healthy headroom at the moment, remembering that we are trailing below our financial target and have healthy headroom. Upon closing of Silmäasema, we are also remembering that it is a partly equity, partly debt deal. So we are in a good position in our balance sheet as well. Post Silmäasema closure.

Ceri Markkula
49:24 - 49:44

Then two questions about recent media stories; to what extent has the media attention occupational healthcare has received lately regarding the lack of transparency, increased customer price tendering, and the cutting out of services?

Ville Pesonen
49:45 - 51:35

Well, if we look at large customers and again SMEs, even though there are a lot of similarities, the differences inside those pockets mean they are still two different breeds in a way. With the large customers, they have, of course, the competencies and resources in negotiating and forming the service packages with us, and there we have seen the post-cyclical pressure early on. And we have seen that in tendering activity. And we have seen that also in terms of pressure on price within the tendering process, which is still of course existing. But the situation is smoothing out and normalizing in that sense, as the media discussion has sparked more engagement and activity within SMEs. It is both negative and positive for us when we think about our sales efforts to SMEs. Typically, the conversion rates are really high. So. So we are able to sell to new SMEs with high conversion rates. So the market is active. But the same, of course, works the other way around. So our existing SME customers are active in tendering, and this balance has been negative during the first half of the year. Now with the heightened sales activities, we are actually balancing even that out. There is still some net churn in SMEs, but we are clearly improving.

Ceri Markkula
51:37 - 51:45

Then there is a question about the group run rate profitability at the moment in IFRS. Adj. EBIT.

Juuso Pajunen
51:46 - 52:28

Uh, thank you. Basically, we are getting from Hohde what we were expecting. We are gaining a dental service that is clearly more profitable than our own dental service, and it has progressed during the nine months between. Between signing and closing, the results are in line with our expectations regarding IFRS 16. You can actually find the bridge at the back of our report where you will see that IFRS 16 debt is roughly €9 million. And then you can assume that the debt component is below €2 million. So with those, you can arrive at the adjusted EBIT numbers. What comes to Hohde?

Ceri Markkula
52:31 - 52:55

Then a question about online eyewear retailers offering prescription glasses. How have you factored this structural pricing pressure into your valuation of Silmäasema ahead of the acquisition, and what impact do you expect it to have on Silmäasema pricing power and long-term profit margins.

Juuso Pajunen
52:55 - 53:38

So first of all, as we have the FCCA process ongoing, we cannot comment on what happens in Silmäasema at the moment, nor can we comment on what we think about the future. What I can say from the deal perspective is that when we were making the acquisition, we conducted a very thorough due diligence, and within that process, we also pressure-tested different types of margin brackets, noting that Silmäasema's EBITDA percentage is within the top tier of optical retail margins. So against that, we have pressure tested different types of expectations, also on lower levels. And our valuation can withstand those levels.

Ville Pesonen
53:39 - 54:03

And maybe to add to that, I would remind everybody of the unique Silmäasema model. It is a fully integrated optical eye care service chain. And that is really unique. What? What is interesting for Terveystalo is to really combine those services and, again, reach out to our customers and also increase the customer base.

Ceri Markkula
54:05 - 54:14

And the question to Ville Iho, could you elaborate a bit further? What are the current unmet needs of your clients that are being addressed by this new strategy?

Ville Pesonen
54:15 - 55:45

Well, we can, if one sort of pressure tests those assumptions a little bit. We have tested in real life from multiple angles the unmet demand, and regardless of the service, if there is at least a tiny part of an elective nature in the service, we can still stimulate the demand with proper packaging, transparent pricing, making it easier to buy and use. We have examples from orthopedics. We have examples from GP services. We have examples from gynecology services. Then a totally new service model modality where there's unmet demand is this type of continuous services. Healthcare service providers are geared for very reactive, high-quality, but reactive episodic services where the patient comes based on his or her needs and goes away. But this does not suffice for quite many conditions, actually, where you need to have constant dialogue with the care provider in a scalable way. And there, the answer from our end is the Wellby platform and services built on that.

Ceri Markkula
55:47 - 55:56

Thank you. This is all for now. Let's start with some final words from Juuso and Ville.

Juuso Pajunen
55:57 - 56:07

Oh, thank you. It has been a very pleasant four years with all of you. And thank you for the good questions and good interaction during these times. And we will meet again.

Ville Pesonen
56:10 - 56:39

Yes, I want to, of course. Welcome, Ville, to Terveystalo. Once again, there are great prospects in our new growth vector, dental, and a lot of energy and ambition there. And then, of course, finally, I want to thank you for a four-year run, which has been exciting. I, of course, expect you to pose questions at the AGM as an investor.

Juuso Pajunen
56:39 - 56:42

That will definitely happen. Tough questions.

Ville Pesonen
56:42 - 56:43

Absolutely.

Ceri Markkula
56:44 - 56:47

Thank you. Have a great rest of the day and week.

Ville Pesonen
56:47 - 56:47

Thank you.

Unknown 2
56:47 - 56:48

Thank you. Thanks.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…